https://www.bloomberg.com/news/articles/2022-02-01/microsoft-deal-for-activision-to-be-reviewed-by-ftc-in-u-s
Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $290
Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $285 to $290.